ZZPZH

Wallstreetcn · Jan 27 at 04:41 AM

With only six months left until July 1, 2026, the implementation of Article 75 of the National Medical Products Administration's "Special Regulations on the Registration of Traditional Chinese Medicine" is entering its final window period. This regulation, referred to in the industry as the "death clause" for proprietary Chinese medicines, clearly states that after three years of implementation starting from July 1, 2023, the contraindications in the instructions will be prohibited

Zhitong · Oct 26, 2025 at 01:29 AM

The second-hand recycling price of ZZPZH has plummeted, recyclers say: the market is too saturated, and there is too much inventory on the market

Wallstreetcn · Oct 24, 2025 at 08:30 AM

The market value of the hundred billion is in jeopardy! After a 20% plunge in profits, how will "Chinese medicine Moutai" ZZPZH turn the tide?

Zhitong · Oct 17, 2025 at 05:41 AM

ZZPZH released its performance for the first three quarters, with a net profit attributable to the parent company of 2.129 billion yuan, a year-on-year decrease of 20.74%

Zhitong · Oct 17, 2025 at 01:39 AM

Cosunter and ZZPZH established a pharmaceutical company with a registered capital of 50 million yuan

Zhitong · Oct 15, 2025 at 08:06 PM

ZZPZH, CICC and others establish new medical industry investment partnership